Skip to main content
Year archive

Innate Pharma — 2020 filings

All 67 regulatory filings released by Innate Pharma (IPH) in 2020, sourced directly from the official regulator.

67 Filings
2020 Period
2020 filings (67)
Filing Released Lang
FORM 6-K
Foreign Filer Report
2020-12-11 English
Innate Pharma retourne les droits de commercialisation de Lumoxiti aux Etats-Unis et en Europe à AstraZeneca
Regulatory Filings
2020-12-11 French
FORM 6-K
Foreign Filer Report
2020-12-03 English
Innate Pharma présentera des données additionnelles d'efficacité pour monalizumab en combinaison avec cetuximab dans les cancers tête et cou au congrès virtuel de l'ESMO immuno-oncologie
Regulatory Filings
2020-12-03 French
Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology virtual congress
Regulatory Filings
2020-12-03 English
FORM 6-K
Foreign Filer Report
2020-12-02 English
Innate Pharma publie son calendrier financier pour 2021
Report Publication Announcement
2020-12-02 French
Innate Pharma 2021 financial calendar
Report Publication Announcement
2020-12-02 English
FORM 6-K
Foreign Filer Report
2020-11-17 English
Half-year financial report - June 30, 2020
Interim / Quarterly Report H1 2020
2020-11-17 English
Rapport financier semestriel au 30 juin 2020
Interim / Quarterly Report H2 2020
2020-11-17 French
Innate Pharma présente ses résultats financiers et l'avancée de son portefeuille au troisième trimestre 2020
Earnings Release 9M 2020
2020-11-17 French
Innate Pharma reports third quarter 2020 financial results and business update
Earnings Release 9M 2020
2020-11-17 English
FORM 6-K
Foreign Filer Report
2020-11-13 English
INNATE PHARMA REÇOIT LE STATUT « PRIME » DE L’AGENCE EUROPÉENNE DU MÉDICAMENT POUR LACUTAMAB DANS LE SYNDROME DE SÉZARY
Regulatory Filings
2020-11-13 French
INNATE PHARMA RECEIVES PRIME DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR LACUTAMAB IN SÉZARY SYNDROME
Regulatory Filings
2020-11-13 English
FORM 6-K
Foreign Filer Report
2020-11-12 English
Participation d'Innate Pharma à de prochains rendez-vous investisseurs
Regulatory Filings
2020-11-12 French
Innate Pharma to participate in upcoming investor conferences
Report Publication Announcement
2020-11-12 English
FORM 6-K
Foreign Filer Report
2020-11-05 English
Franchissement de seuils et déclaration d'intention
Major Shareholding Notification
2020-10-26 French
FORM 6-K
Foreign Filer Report
2020-10-23 English
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
Regulatory Filings
2020-10-23 English
L'inclusion du premier patient dans l'essai clinique de Phase 3 avec monalizumab déclenche un paiement de 50M$ d'AstraZeneca
Regulatory Filings
2020-10-23 French
FORM 6-K
Foreign Filer Report
2020-10-13 English
NOUVEAU NOMBRE D’ACTIONS ET DE DROITS DE VOTE D’INNATE PHARMA AU 1ER OCTOBRE 2020
Share Issue/Capital Change
2020-10-13 French
Number of Shares and Voting Rights of Innate Pharma as of October 1, 2020
Share Issue/Capital Change
2020-10-13 English
FORM 6-K
Foreign Filer Report
2020-09-08 English
Innate Pharma présente ses résultats financiers et l'avancée de son portefeuille au premier semestre 2020
Earnings Release H1 2020
2020-09-08 French
Innate Pharma reports first half 2020 financial results and business update
Earnings Release H2 2020
2020-09-08 English
Prochains rendez-vous investisseurs
Investor Presentation
2020-09-04 French
Upcoming investor conferences
Regulatory Filings
2020-09-04 English
FORM 6-K
Foreign Filer Report
2020-08-12 English
Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er août 2020
Share Issue/Capital Change
2020-08-12 French
FORM 6-K
Foreign Filer Report
2020-08-11 English
Innate Pharma obtient un financement public de 6,8M€ pour ses activités de recherche et développement dans la COVID-19
Capital/Financing Update
2020-08-11 French
Innate Pharma obtains €6.8M in public funding for its COVID-19 research and development activities
Capital/Financing Update
2020-08-11 English
FORM 6-K
Foreign Filer Report
2020-07-29 English
INNATE PHARMA ANNOUNCES PUBLICATION OF EXPLORE COVID-19 TRANSLATIONAL STUDY FINDINGS IN NATURE
Report Publication Announcement
2020-07-29 English
INNATE PHARMA ANNONCE LA PUBLICATION DANS NATURE DES RESULTATS DE L’ETUDE TRANSLATIONNELLE EXPLORE COVID-19
Regulatory Filings
2020-07-29 French
FORM 6-K
Foreign Filer Report
2020-07-16 English
Innate Pharma annonce la nomination de Joyson Karakunnel, MD, MSC, FACP, au poste de Directeur Médical
Board/Management Information
2020-07-16 French
Innate Pharma announces the appointment of Joyson Karakunnel, MD, MSC, FACP as Chief Medical Officer
Board/Management Information
2020-07-16 English
FORM 6-K
Foreign Filer Report
2020-06-24 English
U.S. Food and Drug Administration lifts partial clinical hold on lacutamab TELLOMAK trial in advanced T-cell lymphomas
Earnings Release FY 2020
2020-06-24 English
L'agence américaine du médicament lève la suspension partielle de l'essai TELLOMAK évaluant lacutamab chez les patients présentant un lymphome T avancé
Regulatory Filings
2020-06-24 French
FORM 6-K
Foreign Filer Report
2020-05-20 English
FORM 6-K
Foreign Filer Report
2020-05-14 English
FORM 6-K
Foreign Filer Report
2020-05-12 English
Innate Pharma First Quarter 2020 Report
Earnings Release Q1 2020
2020-05-12 English
FORM 6-K
Foreign Filer Report
2020-05-06 English
FORM 6-K
Foreign Filer Report
2020-04-28 English
FORM 20-F
Annual Report FY 2019
2020-04-24 English
FORM 6-K
Foreign Filer Report
2020-04-24 English
FORM 6-K
Foreign Filer Report
2020-04-17 English
FORM 6-K
Foreign Filer Report
2020-04-14 English
FORM 6-K
Foreign Filer Report
2020-04-14 English
FORM 6-K
Foreign Filer Report
2020-03-10 English
FORM 6-K
Foreign Filer Report
2020-03-10 English
FORM 6-K
Foreign Filer Report
2020-01-14 English
French regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sézary syndrome and mycosis fungoides
Regulatory Filings
2020-01-13 English
L’agence réglementaire française autorise la reprise du recrutement dans l’essai TELLOMAK avec lacutamab chez les patients atteints de syndrome de Sézary et mycosis fongoïde
Regulatory Filings
2020-01-13 French
FORM 6-K
Foreign Filer Report
2020-01-09 English
INNATE PHARMA PROVIDES UPDATE FROM REGULATORY AGENCIES ON LACUTAMAB TELLOMAK TRIAL
Regulatory Filings
2020-01-09 French
FORM 6-K
Foreign Filer Report
2020-01-02 English
L'agence européenne du médicament accepte le dossier de demande d'enregistrement réglementaire de Lumoxiti dans la leucémie à tricholeucocytes en rechute ou réfractaire
Regulatory Filings
2020-01-02 French
The European Medicines Agency accepts the regulatory submission for Lumoxiti in relapsed or refractory hairy cell leukemia
Regulatory Filings
2020-01-02 English